Azitra, Inc.
Azitra, Inc. (AZTR): 3 pipeline candidates · ~12 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.4 months
D/E 0.16 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
N/A
3 buys · 0 sells (180d)
A transparent, data-derived signal for Azitra, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.0M
Cash
$10.1M
Quarterly Burn
$2.5M
Runway
12.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$116K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 469,878 | $110K |
| stonex group inc. | 22,464 | $5K |
| citigroup inc | 1,705 | $399 |
| fmr llc | 150 | $35 |
Frequently asked questions
How many drug candidates are in Azitra, Inc.'s pipeline?
Azitra, Inc. (AZTR) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Azitra, Inc.'s lead drug candidate?
Azitra, Inc.'s most advanced tracked candidate is ATR-01 (Preclinical) for Ichthyosis vulgaris.
What is Azitra, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Azitra, Inc. has approximately 12.4 months of cash runway.
What is Azitra, Inc.'s market capitalization?
Azitra, Inc.'s market capitalization is approximately $3.0M.
Who is the CEO of Azitra, Inc.?
Mr. Francisco D. Salva is the chief executive officer of Azitra, Inc. (AZTR).
Get the full picture on Azitra, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.